Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy.
Many men with newly diagnosed prostate cancer choose not to undergo curative treatment, including patients who cannot be helped by local curative therapies (especially those with metastatic disease) and patients with clinically localized disease who opt for expectant management or noncurative treatments such as androgen ablation. This article reviews the selection of patients for these noncurative approaches, strategies for clinical monitoring, the choices of intervention therapies upon progression, and when to start these therapies.
Messing
Edward M
EM
Department of Urology, University of Rochester, 601 Elmwood Avenue, Box 656, Rochester, NY 14642, USA. edward_messing@urmc.rochester.edu
Thompson
Ian
I
D000465:Algorithms; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000628:therapy*
D000726:Androgen Antagonists